Caduet
Links shared publicly online about this topic
Mylan Inc. - Mylan Launches Generic Version of Caduet® Tablets
investor.mylan.com — “Mylan Inc. - Mylan Launches Generic Version of Caduet® Tablets” View full resource at investor.mylan.com
Most Recently Shared on December 1, 2011 at 5:29 pm By:
Mylan Launches Generic Version of Caduet® Tablets - http://t.co/LEjIBt2Y
Mylan Announces Caduet Settlement Agreement - Drugs.com MedNews
drugs.com — “Mylan Inc. (Nasdaq MYL) today announced that it has entered into a settlement agreement with Pfizer Inc. resolving litigation related to Caduet Tablets, 2.5 mg” View full resource at drugs.com
Most Recently Shared on January 25, 2011 at 5:05 pm By:
Mylan Announces Caduet Settlement Agreement: PITTSBURGH, Jan. 25, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq:... http://bit.ly/hlYFDk #drug
Pfizer and Astellas Announce the Transfer of Distribution Rightsfor Caduet Combination Tablets to Astellas - Drugs.com MedNews
drugs.com — “Pfizer Japan Inc. (hereafter Pfizer, Headquarters Tokyo, President Ichiro Umeda) and Astellas Pharma Inc. (hereafter Astellas, Headquarters Tokyo, President Yos” View full resource at drugs.com
Most Recently Shared on July 8, 2011 at 1:07 pm By:
Pfizer and Astellas Announce the Transfer of Distribution Rightsfor Caduet Combination Tablets to Astellas... http://bit.ly/n3mGCo #drug
Mylan Inc. - Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
investor.mylan.com — “Mylan Inc. - Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)” View full resource at investor.mylan.com
Most Recently Shared on February 5, 2010 at 12:13 pm By:
Mylan Confirms First-to-File Patent Challenge Relating to Caduet. http://bit.ly/aQxHKg
Subscription Center - News Archive
pharmalive.com — “Subscription Center - News Archive” View full resource at pharmalive.com
Most Recently Shared on August 27, 2009 at 6:12 pm By:
Lipitor.com gets Bad Ad slap for cross-promotion sans risk info - Medical Marketing and Media
mmm-online.com — “Pfizer's Lipitor website touted the efficacy of Caduet, Chantix and Norvasc but failed to balance those claims with risk info for the drugs, according to an untitled letter from FDA's Division of Drug Marketing, Advertising and Communication (DDMAC).” View full resource at mmm-online.com
Most Recently Shared on September 6, 2011 at 8:19 pm By:
Lipitor.com gets Bad Ad slap for cross-promotion sans risk info: Pfizer's Lipitor website touted the e... http://t.co/2UWFmcS from MM&M
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
eyeonfda
Author of the blog Eye on FDA - www.eyeonfda.com
-
Drugs and Devices OW
Organizing drug and medical device resources shared by health experts, advocates, and organizations into WisdomCards.
-
Drugs and Devices OW
Organizing drug and medical device resources shared by health experts, advocates, and organizations into WisdomCards.
Advertisement

